Analytical Data
-
Gene name
PKD1
- Application
-
Alternative Names
PC1;Autosomal dominant polycystic kidney disease 1 protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P98161
-
Expression Region
25-636aa
-
Molecular Weight
69.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on PKD1 recombinant protein is grounded in the critical role of the PKD1 gene in the development of polycystic kidney disease (PKD), a genetic disorder characterized by the formation of cysts in the kidneys and other organs. PKD1 encodes the polycystin-1 protein, which is essential for normal kidney function and cellular signaling. Mutations in the PKD1 gene lead to a severe form of the disease, making the study of its protein crucial for understanding the molecular mechanisms underlying PKD. By producing recombinant PKD1 protein, researchers aim to investigate its structural and functional properties, enabling them to uncover how alterations in this protein contribute to disease pathology. Additionally, such studies may facilitate the development of targeted therapies and diagnostic tools. The advancement of recombinant DNA technology and protein expression systems has made it possible to study PKD1 in detail, providing insights that could improve the management and treatment of PKD. Understanding PKD1's interactions with other cellular components and its role in signaling pathways could open new avenues for therapeutic intervention, highlighting the importance of this research in the context of genetic kidney disorders. By characterizing the recombinant PKD1 protein, scientists hope to establish a foundation for future investigations aimed at both understanding and potentially mitigating the effects of this debilitating disease.
